Cancer center leaders lay bare CAR-T makers' struggles—and an unexpected laggard
Fierce Pharma
DECEMBER 13, 2022
Cancer center leaders lay bare CAR-T makers' struggles—and an unexpected laggard. aliu. Tue, 12/13/2022 - 20:12.
Sat.Dec 10, 2022 - Fri.Dec 16, 2022
329 
Here’s How Skilled Nursing Facilities Can Use Virtual Reality Too
MedCity News
DECEMBER 12, 2022
It may take some time to introduce VR into your skilled nursing facility, but it will be worth it for the physical, mental, and social benefit of your residents.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Four ways Biogen is tackling digital innovation in neurological disease
pharmaphorum
DECEMBER 11, 2022
Digital transformation in pharma is not a singular endeavour. It can mean everything from patient-facing disease management apps and wearables to background AI dramatically altering drug discovery or radiological imaging. So, when a life sciences company embarks on a project of digital transformation or innovation, it’s really embarking on multiple projects that span the wide world of pharmaceutical operations.
The Boston Globe Names CCC a Top Place to Work for 2022
Copyright Clearance Center
DECEMBER 13, 2022
December 13, 20 22 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, has been named one of the Top Places to Work in Massachusetts in the 15 th annual employee-based survey project from The Boston Globe. CCC ranked #17, up from #33 last year, in the “ large companies ” category (organizations between 250-999 employees).
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
AstraZeneca, Merck hit with 3-month delay for Lynparza's FDA filing in first-line prostate cancer
Fierce Pharma
DECEMBER 15, 2022
AstraZeneca, Merck hit with 3-month delay for Lynparza's FDA filing in first-line prostate cancer. kdunleavy. Thu, 12/15/2022 - 09:53.
Former VA Secretary Teams up With Daughter to Launch Chronic Pain Care Startup
MedCity News
DECEMBER 15, 2022
Override provides chronic pain patients with a care team that includes a pain physician, a physical therapist, a psychologist and a coach. The company has received $3.5 million in seed funding and has acquired Take Courage Coaching.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
Female Board Members Are Good for Business
PharmExec
DECEMBER 14, 2022
Perspectives from a board member and an aspiring board member on how to increase the number of qualified women on boards.
Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access
Fierce Pharma
DECEMBER 15, 2022
Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access. zbecker. Thu, 12/15/2022 - 10:51.
Health Equity and the Push to Value-Based Care
MedCity News
DECEMBER 14, 2022
To effectively reduce disparities and improve the quality and coordination of care, government, providers, and healthcare organizations are beginning to collaborate on how to best address the factors driving gaps between populations.
mRNA vaccine plus KEYTRUDA® improve melanoma survival
European Pharmaceutical Review
DECEMBER 14, 2022
Moderna, Inc. and Merck have announced that a Phase IIb trial ( NCT03897881 ) of a personalised mRNA cancer vaccine (mRNA-4157/V940), in combination with KEYTRUDA ® , Merck’s anti-PD-1 therapy, demonstrated the first randomised evidence that a personalised neoantigen approach may be beneficial in treating melanoma. Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA ® reduced the risk of recurrence or death by 44 percent (HR=0.56 [95 percent CI, 0.31-1.08]; one-sided p-valu
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Medgadget Visits Healthcare? Expo Taiwan
Medgadget
DECEMBER 16, 2022
This past week, Medgadget was an official media partner with the Healthcareᐩ Expo Taiwan. This four-day annual event brings together healthcare companies from all over Taiwan and the rest of the world. It is also an opportunity for tech companies not typically associated with healthcare, such as ASUS, Intel, and BenQ, to showcase what they’re doing in medicine and healthcare.
Court swats down Vanda's patent suit against Teva and Apotex, clearing the way for Hetlioz generics
Fierce Pharma
DECEMBER 14, 2022
Court swats down Vanda's patent suit against Teva and Apotex, clearing the way for Hetlioz generics. kdunleavy. Wed, 12/14/2022 - 13:54.
How L&D in Regulated Industries Can Move Beyond Just Compliance to Impact [Sponsored]
MedCity News
DECEMBER 12, 2022
The Covid-19 pandemic has forced life sciences companies to take a fresh look at how they do business. But as they reinvent their operations, companies often overlook a critical function: Their learning and development programs.
Pharmacists migration to Australia and New Zealand gets easier now with Academically.ai
Pharmatutor
DECEMBER 10, 2022
Pharmacists migration to Australia and New Zealand gets easier now with Academically.ai. admin. Sat, 12/10/2022 - 15:42. Academically.ai, We are an Australian healthcare education technology (EdTech) start-up based in Sydney. We provide courses that will prepare pharmacists to practice, getting a job and migrate to Australia and New Zealand. To put it simply, we intend to enter the Indian market because the majority of pharmacists are underpaid, and many are unaware of such vast potential outsid
How to Stay Competitive in the Evolving State of Martech
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Amgen’s AMG-133 shows potential in competing with GLP-1RA obesity therapies
Pharmaceutical Technology
DECEMBER 12, 2022
Pipeline therapies within the cardiometabolic space have recently gathered interest following the 20th World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) Hybrid Conference, which took place on 1–3 December. The spotlight was placed on many up-and-coming pharmacotherapies within the space, one of which was Amgen’s obesity therapy, AMG-133, following the company’s announcement of its Phase I therapy results last week, on 1 December.
ASH: With immune thrombocytopenia win, argenx proves efgartigimod’s no one-trick pony in autoimmune disease
Fierce Pharma
DECEMBER 10, 2022
ASH: With immune thrombocytopenia win, argenx proves efgartigimod’s no one-trick pony in autoimmune disease. fkansteiner. Sat, 12/10/2022 - 09:12.
Most Health Systems Are Deploying Home-Based Care to Reduce Hospitalizations & ED Visits, Report Shows
MedCity News
DECEMBER 13, 2022
The majority of health systems now offer some sort of home-based care program, according to a new survey of hospital leaders. The biggest goals of these programs are to improve patient outcomes through reductions in readmissions, hospitalizations and emergency room visits, the report found.
Utrogestan accepted as HRT in Scotland
European Pharmaceutical Review
DECEMBER 12, 2022
The Scottish Medicines Consortium (SMC) has accepted Utrogestan, the only adjunctive micronised progesterone available as hormone replacement therapy (HRT) for use alongside any oestrogen-only HRT for women with an intact uterus. Utrogestan 100mg, a product by Besins Healthcare UK, is a body-identical hormone, which means it has the same molecular structure as the hormone produced by the body.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Kite and Arcellx enter partnership for multiple myeloma therapy development
Pharmaceutical Technology
DECEMBER 12, 2022
Gilead company Kite has entered an international strategic partnership with Arcellx for the joint development and commercialisation of the latter’s T-cell therapy, CART-ddBCMA, to treat relapsed or refractory multiple myeloma patients. The alliance will utilise the capabilities of both firms, including international cell therapy leadership and manufacturing of Kite.
ASH: CSL, uniQure's gene therapy Hemgenix shows durable protection in hemophilia B
Fierce Pharma
DECEMBER 12, 2022
ASH: CSL, uniQure's gene therapy Hemgenix shows durable protection in hemophilia B. kdunleavy. Mon, 12/12/2022 - 14:25.
The White House Wants To Prevent Obesity, but We Also Need To Treat It
MedCity News
DECEMBER 14, 2022
Prevention is critical, and the ideas put forth in the White House’s proposal will likely help many Americans—particularly children—avoid weight gain as well as the downstream effects of obesity and its comorbidities. But more than 42% of U.S. adults already have obesity, and they need help now.
Dapagliflozin approved for heart failure across LVEFs
European Pharmaceutical Review
DECEMBER 12, 2022
The Medicines and Healthcare products Regulatory Agency ( MHRA ) has granted a licence extension for FORXIGA (dapagliflozin) in Great Britain for symptomatic chronic heart failure (HF) across the full spectrum of left ventricular ejection fraction (LVEF). The approval means potentially a further 250,000 patients across the full spectrum of LVEF >40 percent, including HF with reduced, mildly reduced, and preserved ejection fraction (HFrEF, HFmrEF, HFpEF) will be eligible for treatment in Engl
Roles and Responsibilities of Specialized Clinical Supply Experts
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
NICE backs use of Boehringer’s Ofev in IPF from diagnosis
pharmaphorum
DECEMBER 15, 2022
Thousands more UK patients with idiopathic pulmonary fibrosis (IPF) will now be eligible for treatment with Boehringer Ingelheim’s Ofev, following new guidance from health technology assessment agency NICE. Ofev (nintedanib) has been recommended since 2015 for NHS use in IPF patients who have a forced vital capacity (FVC) value of 50% to 80% of normal, but will now be an option for people with less severe disease, i.e. an FVC of more than 80%.
Buyout on Horizon: Amgen floats $28B offer for rare disease drug maker as Sanofi exits bidding war
Fierce Pharma
DECEMBER 12, 2022
Buyout on Horizon: Amgen floats $28B offer for rare disease drug maker as Sanofi exits bidding war. esagonowsky. Mon, 12/12/2022 - 08:18.
Brightside Health Unveils New Program To Battle Suicide Epidemic
MedCity News
DECEMBER 14, 2022
Brightside Health has launched a new program called Crisis Care, specifically designed for individuals with elevated suicide risk. It is initially rolling out in 27 states, with plans to expand across the nation.
Canadian and US developers to trial psychedelic medicines in UK
European Pharmaceutical Review
DECEMBER 13, 2022
North American psychedelic drug developers Mindset, PharmAla, Mydecine and Psyence have signed with clinical research organisation (CRO) Clerkenwell Health to trial therapies for mental health conditions, in London, UK, to benefit from the country’s swift drug regulatory process. The mental health conditions that the companies aim to treat include social anxiety, Autism Spectrum Disorder (ASD), nicotine addiction, major depressive disorder (MDD), and Adjustment Disorder in those facing a termina
Deliver Fast, Flexible Clinical Trial Insights with Spotfire
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Best Healthcare Data Analytics Tools in the Market
Medico Reach
DECEMBER 15, 2022
In modern healthcare industry, medical organizations and institutions generates huge data. To extract insights from this massive complex data organizations are turning towards healthcare data analytics tools to leverage the benefits in this regard effectively. These are software applications that analyze the collected information from a range of sources, including but not limited to clinical research, operational activity, patient care programs and financial reports.
Senators blast Pfizer's proposed COVID vaccine price hike as 'profiteering'
Fierce Pharma
DECEMBER 14, 2022
Senators blast Pfizer's proposed COVID vaccine price hike as 'profiteering'. fkansteiner. Wed, 12/14/2022 - 09:00.
Movano Begins Testing Its Smart Ring for Women With Novant Employees
MedCity News
DECEMBER 14, 2022
Wearables company Movano Health recently partnered with Novant Health to beta test its smart ring — which is designed for women — with the health system’s employees. The program is expected to prepare Movano for its first direct-to-consumer product launch in the first half of next year.
Eisai and Washington University to develop neurodegenerative disease therapies
Pharmaceutical Technology
DECEMBER 15, 2022
Eisai has entered a comprehensive research partnership agreement with Washington University School of Medicine in St Louis, US, to develop potential new therapies for neurodegenerative ailments. Under the deal, the parties intend to develop treatments for diseases including Alzheimer’s and Parkinson’s. The alliance will merge the capabilities of the scientists at Washington University in the basic and clinical research in neurodegenerative ailments, such as dementia, with the wide-ranging expert
ABM Evolution: How Top Marketers Are Using Account-Based Strategies
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
Let's personalize your content